retatrutide triple agonist glp-1 gip glucagon receptors just had its biggest data year yet. In 2026, Eli Lilly's GLP-1/GIP/glucagon receptor posted two major Phase 3 readouts: TRIUMPH-1 (obesity, 2,339 participants) showed a 28.3% average body weight LY3437943, a novel triple glucagon,

doi: 10.1161/CIRCULATIONAHA.118.038868 67 CarusoICignarelliASoriceGPNatalicchioAPerriniSLaviolaLet al

Liraglutide injection The Safety and Clinical Adiposity Liraglutide Evidence (SCALE) trial was a randomized, double-blind, multicenter, international clinical trial that included 3,731 participants who were randomly assigned 2:1 to 3 mg liraglutide or placebo, both including lifestyle modifications

#trizepatide #weightloss #trizepatidejourney #weightlossjouney Is this accurate

This means orforglipron can be taken in pill form to achieve similar effects, including weight loss and other improvements in metabolic health, like better blood sugar control, lower blood pressure, and reduced cholesterol

doi: 10.1007/s12272-013-0051-4

GLP-1Rs agonists exert neuro-humoral actions by stimulating insulin secretion and suppressing glucagon release in a glucose-dependent manner, delaying gastric emptying, and reducing appetite via central nervous system pathways